Anti-platelet therapy: phosphodiesterase inhibitors.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2011-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1365-2125.2011.04034.xPMID 21649691PMCID PMC3195739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS).

  2012cited by this paper
• Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting.

  2011cited by this paper
• Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.

  2011cited by this paper
• Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT

  2011cited by this paper
• ATP and the pathogenesis of COPD.

  2010cited by this paper
• Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.

  2010cited by this paper
• Cilostazol reduces restenosis after carotid artery stenting.

  2010cited by this paper
• Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension

  2010cited by this paper
• Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.

  2010cited by this paper
• Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.

  2010cited by this paper
• Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway.

  2010cited by this paper
• Phosphodiesterase inhibitors for pulmonary hypertension.

  2010cited by this paper
• Effects of Tadalafil on Platelets and Endothelium in Patients With Erectile Dysfunction and Cardiovascular Risk Factors: A Pilot Study

  2010cited by this paper
• Phosphodiesterase inhibitors for pulmonary hypertension.

  2010cited by this paper
• Addition of Cilostazol to Aspirin and a Thienopyridine for Prevention of Restenosis After Coronary Artery Stenting: A Meta‐Analysis

  2010cited by this paper
• Cilostazol augments the inhibition of platelet aggregation in clopidogrel low‐responders

  2010cited by this paper
• Adding Cilostazol to Dual Antiplatelet Therapy Achieves Greater Platelet Inhibition than High Maintenance Dose Clopidogrel in Patients With Acute Myocardial Infarction: Results of the Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With AMI (ACCEL-AMI) Study

  2010cited by this paper
• Phosphodiesterase 2 Mediates Redox-Sensitive Endothelial Cell Proliferation and Angiogenesis by Thrombin via Rac1 and NADPH Oxidase 2

  2009cited by this paper
• Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.

  2009cited by this paper
• Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials.

  2009cited by this paper
• Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo

  2008cited by this paper
• Dipyridamole, cerebrovascular disease, and the vasculature.

  2008cited by this paper
• Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.

  2008cited by this paper
• Potentiation and priming of platelet activation: a potential target for antiplatelet therapy.

  2008cited by this paper
• Translational therapeutics of dipyridamole.

  2008cited by this paper
• Aspirin Plus Dipyridamole Versus Aspirin for Prevention of Vascular Events After Stroke or TIA: A Meta-Analysis

  2008cited by this paper
• Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

  2008cited by this paper
• Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.

  2007cited by this paper
• Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts.

  2007cited by this paper
• Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.

  2007cited by this paper
• A 1-and A 2-Selective Adenosine Antagonists : In Vivo Characterization of Cardiovascular Effects 1

  2006cited by this paper
• Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

  2006cited by this paper
• Effects of anagrelide on megakaryopoiesis and platelet production.

  2006cited by this paper
• Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.

  2006cited by this paper
• Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.

  2006cited by this paper
• Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination.

  2005cited by this paper
• The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.

  2005cited by this paper
• Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet–Monocyte Aggregates

  2005cited by this paper
• RACTS: A Prospective Randomized Antiplatelet Trial of Cilostazol Versus Ticlopidine in Patients Undergoing Coronary Stenting: Long-Term Clinical and Angiographic Outcome

  2005cited by this paper
• Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial.

  2004cited by this paper
• Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association.

  2004cited by this paper
• Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.

  2003cited by this paper
• Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.

  2003cited by this paper
• Pharmacology of phosphodiesterase 5 inhibitors.

  2003cited by this paper
• Cilostazol

  2003cited by this paper
• Dipyridamole Enhances NO/cGMP-Mediated Vasodilator-Stimulated Phosphoprotein Phosphorylation and Signaling in Human Platelets: In Vitro and In Vivo/Ex Vivo Studies

  2003cited by this paper
• Cochrane Review: Dipyridamole for Preventing Major Vascular Events in Patients With Vascular Disease

  2003cited by this paper
• Recovery of platelet function after withdrawal of cilostazol administered orally for a long period.

  2003cited by this paper
• Accumulation of radiolabelled platelets and fibrin on the carotid artery of rabbits after angioplasty: effects of heparin and dipyridamole

  2003cited by this paper
• Platelets in Thrombotic and Non-thrombotic Disorders: Platelet signalling: cAMP and cGMP

  2002cited by this paper
• Vardenafil

  2002cited by this paper
• The pharmacology of cilostazol

  2002cited by this paper
• Effect of Cilostazol on Treadmill Walking, Community‐Based Walking Ability, and Health‐Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta‐Analysis of Six Randomized Controlled Trials

  2002cited by this paper
• PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS

  2002cited by this paper
• The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia.

  2002cited by this paper
• Cyclic GMP‐dependent vasodilatory properties of LASSBio 294 in rat aorta

  2002cited by this paper
• Differential Regulation of Human Platelet Responses by cGMP Inhibited and Stimulated cAMP Phosphodiesterases

  2002cited by this paper
• Modulation of Human Platelet Aggregation by the Phosphodiesterase Type 5 Inhibitor Sildenafil

  2001cited by this paper
• Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

  2001cited by this paper
• Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells

  2001cited by this paper
• Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.

  2001cited by this paper
• A cold start for oral glycoprotein IIb/IIIa antagonists.

  2000cited by this paper
• Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention.

  2000cited by this paper
• Comparison of the Effects of Acetylsalicylic Acid, Ticlopidine and Cilostazol on Primary Hemostasis Using a Quantitative Bleeding Time Test Apparatus

  2000cited by this paper
• Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.

  2000cited by this paper
• Caffeine alters A2A adenosine receptors and their function in human platelets.

  1999cited by this paper
• Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee.

  1999cited by this paper
• Cilostazol

  1999cited by this paper
• Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole.

  1999cited by this paper
• Cyclic Nucleotides and Phosphodiesterases in Platelets

  1999cited by this paper
• Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease

  1999cited by this paper
• Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.

  1999cited by this paper
• Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.

  1999cited by this paper
• Pharmacokinetics of Multiple‐Dose Oral Cilostazol in Middle‐Age and Elderly Men and Women

  1998cited by this paper
• EUROPEAN STROKE PREVENTION STUDY 2: DIPYRIDAMOLE AND ACETYLSALICYLIC ACID IN THE SECONDARY PREVENTION OF STROKE

  1997cited by this paper
• Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.

  1997cited by this paper
• Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

  1997cited by this paper
• Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation.

  1997cited by this paper
• Cilostazol, a cAMP Phosphodiesterase Inhibitor, Attenuates the Production of Monocyte Chemoattractant protein-1 in Response to Tumor Necrosis Factor-α in Vascular Endothelial Cells

  1997cited by this paper
• Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole

  1996cited by this paper
• Interplay between milrinone and adenosine in the inhibition of human platelet response.

  1996cited by this paper
• European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

  1996cited by this paper
• Dipyridamole enhances interleukin-1beta-stimulated nitric oxide production by cultured rat vascular smooth muscle cells.

  1996cited by this paper
• Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study.

  1993cited by this paper
• Effect of antioxidants on chemiluminescence produced by reactive oxygen species.

  1992cited by this paper
• Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals.

  1992cited by this paper
• Antithrombotic therapy in peripheral arterial occlusive disease.

  1992cited by this paper
• Cardiovascular effects of milrinone.

  1991cited by this paper
• Effect of dipyridamole alone and in combination with aspirin on whole blood platelet aggregation, PGI2 generation, and red cell deformability ex vivo in man.

  1991cited by this paper
• The European Stroke Prevention Study

  1991cited by this paper
• Anti-aggregatory effects of physiological concentrations of adenosine in human whole blood as assessed by filtragometry.

  1991cited by this paper
• Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.

  1990cited by this paper
• Purification and characterization of platelet factor XI.

  1990cited by this paper
• Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenicity following injury: influence of salicylate and dipyridamole treatment.

  1990cited by this paper
• Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo.

  1990cited by this paper
• Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells.

  1990cited by this paper
• Dipyridamole potentiates the anti-aggregating effect of endothelium-derived relaxing factor.

  1990cited by this paper
• Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta.

  1989cited by this paper
• Antiplatelet activity of dipyridamole in non anticoagulated whole blood.

  1988cited by this paper
• Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.

  1988cited by this paper

• Impact of Cilostazol versus Cilostazol and Selenium Combination on The Healing of Diabetic Foot Ulcer Patients: A Randomized Controlled Trial

  2026cites this paper
• A real-world pharmacovigilance study of Cilostazol based on the FDA Adverse Event Reporting System:A Cross-Sectional Disproportionality Analysis.

  2026cites this paper
• Clinical pharmacology of antiplatelet drugs: implications for personalized therapy

  2026influential citation
• Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).

  2025cites this paper
• Comparison of effectiveness of aspirin, clopidogrel and cilostazol monotherapy treatment in ischaemic stroke

  2025cites this paper
• Antithrombotic Management for Interventional Pain Procedures

  2025cites this paper
• Advances in the development of phosphodiesterase 5 inhibitors.

  2025cites this paper
• A Deep Learning Methodology for Screening New Natural Therapeutic Candidates for Pharmacological Cardioversion and Anticoagulation in the Treatment and Management of Atrial Fibrillation

  2025cites this paper
• Effect of phosphodiesterase inhibitors on platelet function

  2025cites this paper
• A potential supplemental indication of dipyridamole for contraception: Dipyridamole inhibits mouse sperm fertilization capacity in vitro.

  2025cites this paper
• 6-Cyanodopamine as an endogenous modulator of heart chronotropism and inotropism.

  2025cites this paper
• Antiplatelet therapy through inhibition of P2Y12 and phosphodiesterase receptors by novel synthesis 1,3-dicyclohexylpyrimidine-2,4(1H,3H)-dione derivatives with computational evaluation.

  2025cites this paper
• A personalized approach to current antiplatelet therapy strategies

  2025cites this paper
• The working mechanism of biomarkers related to sumoylation modification in coronary artery disease

  2025cites this paper
• Blockage of the peri-synaptic Schwann cell nicotinic α7 receptor inhibitory drive increases the neuromuscular performance in rats with experimental autoimmune Myasthenia gravis: repurposing dipyridamole usage in myasthenics.

  2025cites this paper
• Rationale and Design of the Efficacy and Safety of Combination of Cilostazol and Gingko biloba Extract EGb 761 in patients with Acute Non-cardioembolic Ischemic Stroke (RENEW): A pilot and feasibility randomized controlled trial.

  2024cites this paper
• Cilostazol niosomes-loaded transdermal gels: An in vitro and in vivo anti-aggregant and skin permeation activity investigations towards preparing an efficient nanoscale formulation

  2024cites this paper
• An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors

  2024cites this paper
• Protein Kinase A Regulates Platelet Phosphodiesterase 3A through an A-Kinase Anchoring Protein Dependent Manner

  2024cites this paper
• Effects of cilostazol on cognitive function and dementia risk: A systematic review and meta-analysis

  2024cites this paper
• Platelets in thrombosis and atherosclerosis: a double-edged sword.

  2024cites this paper
• Heteropterans: a treasure trove of therapeutic proteins

  2024cites this paper
• Long-acting cilostazol versus isosorbide mononitrate for patients with vasospastic angina: a randomized controlled trial

  2024cites this paper
• The pharmacology of antiplatelet agents for primary, secondary, and tertiary prevention of ischemic stroke

  2024cites this paper
• Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health

  2024cites this paper
• Development and Optimization of Dipyridamole- and Roflumilast-Loaded Nanoemulsion and Nanoemulgel for Enhanced Skin Permeation: Formulation, Characterization, and In Vitro Assessment

  2024cites this paper
• Unbiased high-throughput screening of drug-repurposing libraries identifies small-molecule inhibitors of clot retraction

  2024cites this paper
• An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions

  2024cites this paper
• Platelet inhibition by hypochlorous acid involves cAMP signalling.

  2024cites this paper
• Cilostazol for the treatment of distal symmetrical polyneuropathy in diabetes mellitus: Where do we stand?

  2024cites this paper
• Effect of cilostazol on preventing paclitaxel‐induced neuropathy in patients with breast cancer: A randomized controlled trial

  2023cites this paper
• Exploring the Molecular Targets for the Antidepressant and Antisuicidal Effects of Ketamine Enantiomers by Using Network Pharmacology and Molecular Docking

  2023cites this paper
• Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases

  2023cites this paper
• Current concepts and novel targets for antiplatelet therapy

  2023cites this paper
• A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19

  2023cites this paper
• Mutations in phosphodiesterase 3A (PDE3A) Cause Hypertension Without Cardiac Damage.

  2023cites this paper
• Effects of orally administered pimobendan on platelet function in healthy adult cats.

  2023cites this paper
• Role of the NO-GC/cGMP signaling pathway in platelet biomechanics

  2023cites this paper
• European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases.

  2023cites this paper
• Retinoblastoma vulnerability to combined de novo and salvage pyrimidine ribonucleotide synthesis pharmacologic blockage

  2023cites this paper
• PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets

  2023cites this paper
• Antiplatelet Effects of Selected Xanthine-Based Adenosine A2A and A2B Receptor Antagonists Determined in Rat Blood

  2023influential citation
• Drugs targeting adenosine signaling pathways: A current view.

  2023cites this paper
• Antiplatelet Resistance: A Review of Concepts, Mechanisms, and Implications for Management in Acute Ischemic Stroke and Transient Ischemic Attack

  2023cites this paper
• Novel strategies in antithrombotic therapy: targeting thrombosis while preserving hemostasis

  2023cites this paper
• Beyond the heart - Exploring the therapeutic potential of PDE3 inhibitors

  2023cites this paper
• The inhibitory effects of glabridin on human platelet aggregation and thrombus formation

  2023cites this paper
• Daidzein Inhibits Human Platelet Activation by Downregulating Thromboxane A2 Production and Granule Release, Regardless of COX-1 Activity

  2023cites this paper
• Polyphenol-Rich Beverage Consumption Affecting Parameters of the Lipid Metabolism in Healthy Subjects

  2023cites this paper
• The Inhibitory Effects of Protaetia brevitarsis seulensis Larvae Extract on Human Platelet Aggregation and Glycoprotein IIb/IIIa Expression

  2023cites this paper
• Synthetic coumarin derivatives with anticoagulation and antiplatelet aggregation inhibitory effects

  2023cites this paper
• A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection

  2023cites this paper
• Pharmacological actions of morusinol on modulation of platelet functions via integrin αIIb/β3 signaling

  2023cites this paper
• Molecular profiling of the stroke-induced alterations in the cerebral microvasculature reveals promising therapeutic candidates

  2023cites this paper
• Antiplatelet strategies: past, present, and future.

  2023cites this paper
• No impact of polymorphism in the phosphodiesterase 5A gene in Cavalier King Charles Spaniels on pimobendan‐induced inhibition of platelet aggregation response

  2023cites this paper
• Dipyridamole does not have any additive effect on the prevention of COVID-19 coagulopathy.

  2022cites this paper
• A Review on Phosphodiesterase-5 Inhibitors as a Topical Therapy for Erectile Dysfunction.

  2022cites this paper
• Novel approaches to antiplatelet therapy.

  2022cites this paper
• Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis

  2022cites this paper
• Adenosine diphosphate‐induced aggregation is enhanced in platelets obtained from patients with thrombotic primary antiphospholipid syndrome (t‐PAPS): Role of P2Y12‐cAMP signaling pathway

  2022cites this paper
• Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches

  2022cites this paper
• Multiple PDE3A modulators act as molecular glues promoting PDE3A-SLFN12 interaction and induce SLFN12 dephosphorylation and cell death.

  2022cites this paper
• Cilostazol combined with P2Y12 receptor inhibitors: A substitute antiplatelet regimen for aspirin‐intolerant patients undergoing percutaneous coronary stent implantation

  2022cites this paper
• Effects of Dose Titration on Dipyridamole-Induced Headache: A Randomized, Double-Blind Clinical Trial

  2022cites this paper
• Effect of Tadalafil in Comparison with Clobetasol ointment in induced Psoriasis in Mice Male

  2022cites this paper
• Quantification of cyclic AMP and cyclic GMP levels in Krebs-Henseleit solution by LC-MS/MS: Application in washed platelet aggregation samples.

  2022cites this paper
• Impaired Platelet Function and Thrombus Formation in PDE5A-Deficient Mice

  2022cites this paper
• Pharmacological Actions of 5-Hydroxyindolin-2 on Modulation of Platelet Functions and Thrombus Formation via Thromboxane A2 Inhibition and cAMP Production

  2022cites this paper
• Synthesis of pyrimidine-containing alkaloids.

  2022cites this paper
• The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders

  2022cites this paper
• Optogenetic manipulation of cyclic guanosine monophosphate to probe phosphodiesterase activities in megakaryocytes

  2022cites this paper
• Abnormal platelet aggregation in pediatric pulmonary hypertension

  2022cites this paper
• The role of platelets, neutrophils and endothelium in COVID-19 infection

  2022cites this paper
• Altered platelet functions during treatment with apremilast for psoriatic arthritis: A case report.

  2022cites this paper
• The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis

  2022cites this paper
• Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway

  2022cites this paper
• Clinical pharmacology of antiplatelet drugs

  2022cites this paper
• Cilostazol for Secondary Stroke Prevention

  2021cites this paper
• The aminoalkylindole, BML-190, negatively regulates chitosan The aminoalkylindole, BML-190, negatively regulates chitosan synthesis via the cAMP/PKA1 pathway in Cryptococcus synthesis via the cAMP/PKA1 pathway in Cryptococcus neoformans [preprint] neoformans [preprint]

  2021cites this paper
• Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors

  2021cites this paper
• Homodinuclear copper(II) and zinc(II) complexes of a carboxylate-rich ligand as synthetic mimics of phosphoester hydrolase in aqueous solutions.

  2021cites this paper
• Effects of pentoxifylline on canine platelet aggregation

  2021cites this paper
• Comparison of two individualized antithrombotic protocols in heartware HVAD recipients.

  2021cites this paper
• Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet Functions

  2021influential citation
• Dipyridamole induces the phosphorylation of CREB to promote cancer cell proliferation

  2021cites this paper
• Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis.

  2021cites this paper
• Dose dependent effect of cilostazol in induced testicular ischemia reperfusion via modulation of HIF/VEGF and cAMP/SIRT1 pathways.

  2021cites this paper
• Cancer-associated-platelet-inspired nanomedicines for cancer therapy.

  2021cites this paper
• Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches

  2021cites this paper
• Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile

  2021cites this paper
• Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury.

  2021cites this paper
• An Overview of COVID-19 and Its Vaccines

  2021cites this paper
• Medical therapy for cardiovascular and limb-related risk reduction in critical limb ischemia

  2021cites this paper
• The Role of Cilostazol and Inflammation in Cognitive Impairment After Ischemic Stroke

  2021cites this paper
• Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications

  2021cites this paper
• Nutritional Management Approach for Possible Prevention of COVID-19 Infection and Transmission in Sub-Saharan and Biodiversity Endowed Countries

  2021cites this paper
• Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases

  2021cites this paper
• ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody

  2021cites this paper
• Platelet Abnormalities in Chronic Kidney Disease and Their Implications for Antiplatelet Therapy.

  2021cites this paper